PVH
TCRT icon

Psagot Value Holdings’s Alaunos Therapeutics TCRT Stock Holding History

Psagot Value Holdings’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-34
Closed -$3K – 623
2023
Q1 		$3K Buy
+34
New +$3.24K ﹤0.01% 388

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Psagot Value Holdings's TCRT Position: Q2 2023 in Review

Psagot Value Holdings sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 34 shares — an estimated $3K sold.

Psagot Value Holdings first reported a position in TCRT in Q1 2023 and held it in 1 quarter. The position peaked at $3K in Q1 2023. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Psagot Value Holdings reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Psagot Value Holdings sold 34 Alaunos Therapeutics shares in Q2 2023, an estimated $3K.
  • Psagot Value Holdings first reported a position in Alaunos Therapeutics in Q1 2023 and held it in 1 quarter.
  • Psagot Value Holdings's Alaunos Therapeutics position peaked at $3K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Psagot Value Holdings's 13F filing for Q2 2023, filed 3 Aug 2023.